Cargando…

Neoadjuvant Endocrine Therapy (NET) in breast cancer – COVID setting

Detalles Bibliográficos
Autores principales:	Bardoli, Antonio, Muttalib, Masoom
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Ltd. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802073/ http://dx.doi.org/10.1016/j.ejso.2021.11.022

Ejemplares similares

Breast cancer surgery during the COVID-19 pandemic: A prospective observational study in a single centre
por: Callan, Rory, et al.
Publicado: (2021)

Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art
por: Lerebours, Florence, et al.
Publicado: (2021)

The Present and Future of Neoadjuvant Endocrine Therapy for Breast Cancer Treatment
por: Martí, Covadonga, et al.
Publicado: (2021)

Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives
por: Barroso-Sousa, Romualdo, et al.
Publicado: (2016)

Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives
por: Barchiesi, Giacomo, et al.
Publicado: (2020)

Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic
por: Park, Ko Un, et al.
Publicado: (2021)

Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031)
por: Suman, Vera J., et al.
Publicado: (2022)

Effect of Targeted Agents on the Endocrine Response of Breast Cancer in the Neoadjuvant Setting: A Systematic Review
por: Grassadonia, Antonino, et al.
Publicado: (2015)

Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication
por: Ueno, Takayuki, et al.
Publicado: (2019)

Multidisciplinary Approach to Neoadjuvant Endocrine Therapy in Breast Cancer: A Comprehensive Review
por: Reinert, Tomás, et al.
Publicado: (2016)

Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool
por: Chia, Y H, et al.
Publicado: (2010)

Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer
por: Long, Mengping, et al.
Publicado: (2022)

Network Meta-Analysis of the Effectiveness of Neoadjuvant Endocrine Therapy for Postmenopausal, HR–Positive Breast Cancer
por: Wang, Wei, et al.
Publicado: (2016)

Early metabolic response of breast cancer to neoadjuvant endocrine therapy: comparison to morphological and pathological response
por: Boughdad, Sarah, et al.
Publicado: (2020)

Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes
por: Cao, Lifen, et al.
Publicado: (2021)

The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer
por: Zhang, Ailin, et al.
Publicado: (2021)

Neoadjuvant endocrine therapy in ER-positive breast cancer: evolution, indication, and tailored treatment strategy
por: Jeong, Hyehyun, et al.
Publicado: (2023)

Aberrant Regulation of RAD51 Promotes Resistance of Neoadjuvant Endocrine Therapy in ER-positive Breast Cancer
por: Jia, Yan, et al.
Publicado: (2019)

Contralateral parenchymal enhancement on breast MRI before and during neoadjuvant endocrine therapy in relation to the preoperative endocrine prognostic index
por: Ragusi, Max A. A., et al.
Publicado: (2020)

Palbociclib in breast cancer neoadjuvant setting
por: Duarte, Sílvia Alexandra Cabral, et al.
Publicado: (2021)

Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy
por: Murphy, Brenna M., et al.
Publicado: (2021)

Neoadjuvant endocrine therapy for luminal breast cancer treatment: a first-choice alternative in times of crisis such as the COVID-19 pandemic
por: Martí, Covadonga, et al.
Publicado: (2020)

Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer
por: Kantor, Olga, et al.
Publicado: (2020)

Use of Ultrasound and Ki–67 Proliferation Index to Predict Breast Cancer Tumor Response to Neoadjuvant Endocrine Therapy
por: Liebscher, Sean C., et al.
Publicado: (2023)

The immune microenvironment characterisation and dynamics in hormone receptor–positive breast cancer before and after neoadjuvant endocrine therapy
por: Oner, Gizem, et al.
Publicado: (2023)

Prognostic value of breast MRI characteristics before and during neoadjuvant endocrine therapy in patients with ER+/HER2- breast cancer
por: Ragusi, Max AA, et al.
Publicado: (2021)

Molecular downstaging: a new paradigm for neoadjuvant endocrine therapy
por: Ferraro, Emanuela, et al.
Publicado: (2020)

Pharmacogenomics of endocrine therapy in breast cancer
por: Ingle, James N
Publicado: (2013)

Long-Term Outcome of Neoadjuvant Endocrine Therapy with Aromatase Inhibitors in Elderly Women with Hormone Receptor-Positive Breast Cancer
por: Grassadonia, Antonino, et al.
Publicado: (2014)

Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer
por: Goncalves, Rodrigo, et al.
Publicado: (2017)

Effectiveness of a Short Duration of Neoadjuvant Endocrine Therapy in Patients with HR+ Breast Cancer—An NCDB Analysis (2004–2016)
por: Goldbach, Macy M., et al.
Publicado: (2021)

Neoadjuvant chemotherapy combined with endocrine therapy for hormone receptor-positive breast cancer: A systematic review and meta-analysis
por: Ma, Hong-Fang, et al.
Publicado: (2023)

Efficacy of neoadjuvant endocrine therapy in patients with poorly differentiated neuroendocrine carcinoma of the breast: A case report
por: Zhang, Yonglin, et al.
Publicado: (2020)

Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer
por: Kim, Hee Jeong, et al.
Publicado: (2020)

Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy
por: Ueno, Takayuki, et al.
Publicado: (2016)

Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial
por: Ellis, Matthew J., et al.
Publicado: (2008)

Assessment of preoperative axillary nodal disease burden: breast MRI in locally advanced breast cancer before, during and after neoadjuvant endocrine therapy
por: Reis, Joana, et al.
Publicado: (2022)

Correction to: Effectiveness of a Short Duration of Neoadjuvant Endocrine Therapy in Patients with HR+ Breast Cancer—An NCDB Analysis (2004–2016)
por: Goldbach, Macy M., et al.
Publicado: (2021)

Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial
por: Ueno, Takayuki, et al.
Publicado: (2018)

Neoadjuvant systemic therapy for breast cancer
por: Zaborowski, Alexandra M, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bpsqhm0hqcip138uc5tgu82fn7